Esprinet S.p.A.

As of June 30, 2026, Esprinet S.p.A. carries a market capitalization of 332.01M, placing it among publicly traded companies globally. Its enterprise value stands at 664.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Esprinet S.p.A.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Esprinet S.p.A. has 49.44M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Esprinet S.p.A. maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Esprinet S.p.A. recorded 7.75M in income tax expense.

As of the close on October 22, 2026, Esprinet S.p.A.'s stock has gained approximately 32.82% over the past 52 weeks. The 50-day moving average sits at 7.71, while the 200-day moving average is 6.66.

As of June 30, 2026, Esprinet S.p.A. holds 112.20M in cash and equivalents against 445.00M in total debt, resulting in a net debt position of 210.74M. Total book value stands at 376.85M, with working capital of 311.77M providing operational flexibility.

Esprinet S.p.A.'s most recent stock split took place on May 16, 2005 with a 1:10 split ratio.